HeartSciences Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -97.5% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Year-end price | $4.73 | $3.09 | $3.82 | $17.10 | $84.00 | |
| P/S | 344.1x | 4270.6x | 1374.0x | 175.8x | 344.1x | 194.3x |
| P/B | 18.4x | 81.6x | 29.1x | 0.4x | 7.7x | — |
| EPS | -$3.48 | -$9.34 | -$18.74 | -$80.00 | -$145.00 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ICUSeaStar Medical Holding Corp | $3.09 | — | 3.1x | — | -356.87% | $13.62M |
| GTBPGT Biopharma, Inc. | $0.30 | 0.1x | 3.8x | — | -113.52% | $13.53M |
| INTSIntensity Therapeutics Inc | $4.25 | — | 1.4x | — | -195.88% | $13.88M |
| KALAKALA BIO, Inc. | $0.69 |
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
Company description provided by Yahoo Finance.
| Profit margin | -123384.27% | -211666.47% | -201499.52% | -35511.87% | -123384.27% | -33592.57% |
| ROE | -3400.03% | -4044.00% | -4272.16% | -90.27% | -2756.06% | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.5x |
| — |
| -345.32% |
| $13.35M |
| RGNTRegentis Biomaterials Ltd | $2.00 | — | 2.2x | — | — | $14.05M |
| PHIOPhio Pharmaceuticals Corp. | $1.13 | — | 1.0x | — | -113.71% | $13.13M |